REVIEWCo-infection with human immunodeficiency virus and tuberculosis in Asia
Introduction
The foremost cause of death due to human immunodeficiency virus (HIV) in developing countries is tuberculosis (TB), responsible for at least 13%, and perhaps ⩾30% of all deaths.1, 2 In turn, HIV-induced immunosuppression is a substantial contributor to TB reactivation; one study in Cambodia suggested nearly one-quarter of HIV cases from January 2004 to February 2005 had active TB.3 Furthermore, the problem is growing despite the anti-retroviral therapy (ART) “roll-out” in developing countries for at least four reasons. First, there is a substantial lag in ART availability compared with the clinical need in Asia. Second, the ongoing high incidence of HIV continually generates a cadre of newly TB-at-risk persons. Third, the increasing age of previously HIV-infected persons increases the risk of Mycobacterium tuberculosis reactivation due to advancing immunosuppression. Fourth, there remain serious program limitations that inhibit application of measures to control and prevent both HIV and TB, e.g. directly observed therapy-short course (DOTS).4, 5, 6, 7, 8, 9 HIV transmission is expanding to the huge and populous Asian continent rapidly. A metaphor is apt: this is a time when oil (HIV) is poured into the fire (TB-infected persons) in Asia.
Of an estimated 8.9 million active TB cases worldwide in 2004, the World Health Organization (WHO) estimated that 13% were in HIV-infected persons, perhaps double the proportion of a decade ago (Table 1).2, 10, 11 This reflects the Asian situation in which more and more TB cases are attributable to HIV co-infection and immunosuppression.12, 13 In the context of this on-going challenge in research, as well as in both training and service, the 40th anniversary meeting organizers of the U.S.–Japan Cooperative Medical Science Program (USJCMSP) (Kyoto, Japan, December 2005) chose to highlight this link through a joint symposium in the form of the USJCMSP 10th International Conference on Emerging Infectious Diseases in the Pacific Rim, involving the US–Japan Panels on AIDS14 and Panels on Tuberculosis-Leprosy. This article serves to highlight and update selected themes that were highlighted in the conference and that remain potent priorities in the area of co-infection research.
The synergy of HIV and TB takes several forms (Fig. 1). HIV-induced immunosuppression increases the likelihood that quiescent M. tuberculosis will reactivate.15 The newly active TB patient is now infectious for TB whereas without the HIV co-infection, the patient might have remained uninfectious. TB itself up-modulates the host immune system; an activated T-cell that is activated in response to infection from M. tuberculosis (or a number of other infections such as helminthes or herpeviruses) produces more HIV than a quiescent cell such that HIV expression increases in the face of co-infections.16 Higher HIV viral loads increase the rate of disease progression and also increase HIV infectiousness.17, 18, 19, 20, 21 It may be that TB infection in the HIV-uninfected person results in activated T-cells that are now more susceptible to HIV upon exposure. Hence, prevention and treatment of either infection can be expected to assist in the control of the other.22 HIV and TB are clearly synergistic, such that their joint clinical management must be considered an essential component of global primary care and public health, as has been argued as well for HIV and sexually transmitted infections.23, 24, 25, 26, 27, 28
An anchor for any joint program of HIV and TB control and prevention is to promptly and accurately identify and discriminate patients who are infected with one or both agents. Two points are key in interrupting further spread of HIV–TB: (1) efficient diagnosis and initiation of ART and/or modified DOTS, when appropriate, with longer-than-usual course of anti-TB drugs and (2) proper management of the patient after beginning of the treatment such that drug interactions, side effects, the immune reconstitution syndrome (IRIS) are managed well, and that drug adherence is facilitated. HIV programs must screen and treat all discovered TB cases; TB programs must offer HIV counseling and testing with proper bridges to HIV care. WHO seeks to expand DOTS, whose success rate is high when properly implemented for 6–9 months for each patient. However, none of this is easy in the face of infrastructure and manpower limitations; research is essential to guide us in program evaluations and to offer future improvements.
Many research questions are being addressed in the clinical interface of HIV and TB,29, 30 some of which were highlighted at the 10th International Conference on Emerging Infectious Diseases in the Pacific Rim TB–HIV co-infection symposium. A few of these are listed here:
- 1.
By what molecular and cellular mechanisms do TB infections upregulate HIV expression?16
- 2.
What is the nature of the immunological changes induced by HIV infection that permit reactivation of M. tuberculosis?
- 3.
In the immunosuppressed, co-infected patient with HIV and TB, what is the optimal approach to treatment in order to avoid the paradoxical worsening of TB through the IRIS?31, 32, 33, 34
- 4.
What is the extent to which certain anti-TB and anti-retroviral drugs interact such that doses must be modified or selected combinations avoided?35, 36, 37, 38, 39
- 5.
What innovative TB diagnostics can be developed, such as the microscopic observation drug susceptibility assay (MODS), to improve the ability of care providers to identify TB and its resistant strains rapidly and effectively, especially in settings with suboptimal skin testing, radiologic, microscopic, and/or microbiologic capacities?40, 41, 42, 43, 44
- 6.
How can we develop vaccines for HIV and for TB?45, 46, 47, 48, 49, 50, 51, 52
- 7.
How can we develop new classes of drugs for HIV and for TB to address cost, toxicities, and drug-resistant organisms?53, 54, 55, 56
- 8.
How can we identify recently infected persons even before they mount easily identifiable immune (for HIV) and/or inflammatory (for TB) responses?57, 58, 59, 60
- 9.
How can we reduce high risk behavior to reduce transmission, such as high risk sex for HIV and alcohol abuse for TB (and HIV)?61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
Additional research questions are in the realm of program implementation:
- 1.
How can TB and HIV programs be integrated to the benefit of the co-infected patient?73, 74
- 2.
How can isoniazid prophylaxis be integrated into HIV therapy regimens?75, 76, 77, 78, 79
- 3.
How can obstacles to HIV testing and counseling in TB clinics be overcome?74
- 4.
What is an approach globally to implement TB resistance surveillance for HIV-infected patients who are at highest risk of the emergence of multiple-drug-resistant (MDR) and extensive-drug-resistant (XDR) TB strains? What basic laboratory services can be established and sustained for TB testing in resource-limited, rural settings?41
- 5.
How can drug supplies and delivery be guaranteed for both HIV and TB to avoid drug resistance?80, 81, 82, 83
- 6.
How can successful behavioral and community-organization approaches be applied to maximize drug adherence for both HIV and TB therapy?84, 85, 86, 87, 88
- 7.
How can contact tracing be developed and sustained in all venues of need?89, 90, 91, 92, 93, 94
- 8.
What are programs that can integrate institutional TB and HIV control programs (e.g. jails and prisons, orphanages, homeless shelters, long-term mental health facilities, health care facilities) with community programs? Program features should include bridges to community care for persons discharged from institutions, reducing risk to family members who visit loved ones in institutions, and protection of institutional employees.95, 96, 97, 98, 99, 100, 101, 102
- 9.
How do we train health practitioners adequately in both HIV and TB care and prevention, building on many decades of experience in the TB and leprosy fields, both of which depend on long-term sustenance of anti-microbial therapy?103
Global investigators are addressing these and other questions. HIV is far better funded in the research arena than is TB. In the United States, fully $2.89 billion (11%) of the total fiscal year 2007 president's budget (i.e., proposed) for the National Institutes of Health in the US was devoted to HIV/AIDS research and development, for example.104 Since TB research is an opportunistic infection, acknowledging the linkages between the two infectious diseases and permitting substantial increases in TB research funding will be beneficial.
Asia is characterized by highly variable HIV transmission patterns. In China, injection drug use (IDU) and commercial sex work (CSW) are driving the HIV epidemic.72 In India, IDU is most relevant in the northeast, but heterosexual transmission drives the larger epidemic in South India.105 Thailand, Vietnam, Burma (Myanmar), Tajikistan, and Pakistan, among others in Asia, have serious IDU problems.106, 107, 108, 109, 110, 111 Men who have sex with men contribute to risk in Hong Kong, Taiwan, China, Thailand, India, and elsewhere in Asia.112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130 Given high background rates of TB, no subgroup with HIV infection can be considered at low TB risk.
TB in Asia tracks with poverty, crowding, poor public health and medical infrastructures, and prisons; it can be controlled with familiar approaches such as DOTS, even in the context of HIV co-infection.131, 132, 133, 134, 135 HIV–TB co-infection is common in all regions where HIV is most prevalent, and can be extremely high among certain subgroups, such as IDUs and prisoners. Only the higher income nations of Asia are controlling TB adequately.
A principal concern for Asia is its vast population and crowding that works towards efficient TB transmission where public health infrastructures are inadequate for screening, case finding, and successful therapy (Fig. 2).136 Exacerbated by HIV, TB will continue to be a major cause of mortality and illness in Asia. And since HIV continues to rise in Asia, including China and India that house 2.3 billion (>35%) of the world's 6.5 million persons, the potential for HIV–TB co-expansion can well be viewed as a looming disaster for Asia. The economics of HIV and TB indicate that their joint control is cost-effective, including tackling the costly challenge of MDR–TB.137, 138, 139, 140, 141, 142 U.S.-funded efforts to expand the DOTS program in Mexico, Haiti, and the Dominican Republic, among other nations, reduce TB-related morbidity and mortality among migrants to the United States, producing a net cost savings for the United States.143 This may be wise for higher income nations in Asia to consider; their own overseas donor support can help reduce the overall burden of TB in Asia, protecting even the richer nations. This is timely as a new threat faces Asia, the potential emergence of so-called XDR–TB, or extensively drug-resistant TB, as has occurred in South Africa.144 The theme of HIV–TB co-infection will remain a priority for the U.S.–Japan Cooperative Medical Science Program as it seeks to engage a broader Asian constituency for its mission to nurture collaborative scientific work between the United States, Japan, and Asian partners.
Section snippets
Acknowledgments
This work was supported by the U.S.–Japan Cooperative Medical Science Program. Drs. Vermund and Yamamoto were co-chairs of the US–Japan Panels on AIDS at the time of the December 2005 Kyoto meeting.
Funding: None
Competing interests: None declared
Ethical approval: Not required
References (144)
- et al.
HIV-1 drug resistance in Thailand: before and after National Access to Antiretroviral Program
J Clin Virol
(2005) - et al.
The effect of infection with Mycobacterium tuberculosis on T-cell activation and proliferation in patients with and without HIV co-infection
J Infect
(2005) - et al.
Sexually transmitted diseases and human immunodeficiency virus. Epidemiologic synergy?
Infect Dis Clin North Am
(1993) - et al.
Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy
J Infect
(2006) - et al.
Paradoxical worsening of tuberculosis in HIV-infected persons
Chest
(2001) - et al.
Infrequent MODS TB culture cross-contamination in a high-burden resource-poor setting
Diagn Microbiol Infect Dis
(2006) - et al.
Progress in tuberculosis vaccine development
Curr Opin Immunol
(2006) - et al.
Smoking and tuberculosis: the epidemiological association and immunopathogenesis
Trans R Soc Trop Med Hyg
(2006) - et al.
Alcohol intoxication and sexual risk behaviors among rural-to-urban migrants in China
Drug Alcohol Depend
(2005) - et al.
HIV in prison in low-income and middle-income countries
Lancet Infect Dis
(2007)
Prevention of infectious disease transmission in correctional settings: a review
Public Health
Impact of HIV infection on tuberculosis
Postgrad Med J
Screening HIV-infected persons for tuberculosis—Cambodia, January 2004–February 2005
MMWR Morb Mortal Wkly Rep
HIV/AIDS care and treatment in three provinces in northern Thailand before the national scale-up of highly-active antiretroviral therapy
Southeast Asian J Trop Med Public Health
Current progress of China's free ART program
Cell Res
Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program
Clin Infect Dis
Thailand's response to the HIV epidemic: yesterday, today, and tomorrow
AIDS Educ Prev
Preventing mother-to-child HIV transmission: the first year of Thailand's national program
JAMA
The growing burden of tuberculosis: global trends and interactions with the HIV epidemic
Arch Intern Med
Tuberculosis in patients with human immunodeficiency virus infection
Semin Respir Infect
Tuberculosis epidemiology in India: a review
Int J Tuberc Lung Dis
The ‘bear trap’: the colliding epidemics of tuberculosis and HIV in Russia
Int J STD AIDS
International HIV and AIDS prevention: Japan/United States collaboration
J Acquir Immune Defic Syndr Hum Retrovirol
A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection
N Engl J Med
Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan
J Infect Dis
Use of antiretroviral drugs to prevent sexual transmission of HIV
Curr Clin Top Infect Dis
Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa
AIDS Res Hum Retroviruses
Viral load and heterosexual transmission of human immunodeficiency virus type. Rakai Project Study Group
N Engl J Med
Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study
AIDS
The impact of HIV/AIDS on the control of tuberculosis in India
Proc Natl Acad Sci USA
HIV and sexually transmitted diseases: lethal synergy
Top HIV Med
From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection
Sex Transm Infect
Sexually transmitted diseases and HIV infection: implications for control and prevention
J Indian Med Assoc
Human immunodeficiency virus (HIV) and sexually transmitted diseases (STDs)
Indian J Med Res
The role of sexually transmitted diseases in HIV transmission
Nat Rev Microbiol
Developing a human immunodeficiency virus/acquired immunodeficiency syndrome therapeutic research agenda for resource-limited countries: a consensus statement
Clin Infect Dis
Priorities for antiretroviral therapy research in Sub-Saharan Africa: a 2002 consensus conference in Zambia
J Acquir Immune Defic Syndr
Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis
Antivir Ther
Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden
AIDS
API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India
J Assoc Physicians India
Antiretroviral therapy and TB
Trop Doct
Drug–drug interactions and tolerance in combining antituberculosis and antiretroviral therapy
Expert Opin Drug Saf
HIV-TB co-infection: epidemiology, diagnosis and management
Indian J Med Res
Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status
Int J Tuberc Lung Dis
Microscopic-observation drug-susceptibility assay for the diagnosis of TB
N Engl J Med
Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings
J Clin Microbiol
Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosis
J Clin Microbiol
Progress and obstacles in the development of an AIDS vaccine
Nat Rev Immunol
Cited by (17)
Tuberculosis and nature's pharmacy of putative anti-tuberculosis agents
2016, Acta TropicaCitation Excerpt :In 2008, WHO estimated that the largest number of new TB cases occurred in South-East Asia, which accounted for 34% of incident cases globally (WHO, 2010a). By the year 2007, Asia had 60% of the global burden of TB (Vermund and Yamamoto, 2007). In the former Soviet Union, TB also reached epidemic proportions (Toungoussova et al., 2006).
Tuberculosis and HIV co-infection-focus on the Asia-Pacific region
2015, International Journal of Infectious DiseasesCitation Excerpt :However, these countries have reduced visibility due to uncertain data quality and relatively small population sizes, which limit their influence on aggregated regional and global figures. Similar to other parts of the world, TB incidence rates in the Asia-Pacific region are broadly associated with poverty and limited public health infrastructure.6 Specific factors that contribute to TB vulnerability at the population level include rising rates of diabetes on the one hand, with persistent high rates of malnutrition on the other.7
Novel polymorphisms in TICAM2 and NOD1 associated with tuberculosis progression phenotypes in Ethiopian populations
2018, Global Health, Epidemiology and GenomicsAspects associated with drug resistance in people with tuberculosis/HIV: An integrative review
2020, ACTA Paulista de EnfermagemPrevalence of TB/ HIV co-infection in Iran: A systematic review and meta-analysis
2019, Annali di Igiene Medicina Preventiva e di Comunita